Nivolumab + Ipilimumab
Treatment for Mesothelioma
Typical Dosage: Nivolumab 360mg Q3W + Ipilimumab 1mg/kg Q6W x4, then Nivolumab monotherapy
Effectiveness
75%
Safety Score
35%
Clinical Trials
18
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
Nivolumab 360mg Q3W + Ipilimumab 1mg/kg Q6W x4, then Nivolumab monotherapy
Time to Effect
2-4 months
Treatment Duration
Up to 2 years for Nivolumab, Ipilimumab 4 doses
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$244,000
Monitoring:$12,000
Side Effect Mgmt:$15,000
Total Annual:$271,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$120,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$677,500
Cost per Remission
$5,420,000
Comparison vs Pemetrexed + Cisplatin
Cost Difference
+$251,000/year
More expensive
QALY Difference
+0.30 QALYs
Better outcomes
Dominance
No dominance
Nivolumab + Ipilimumab Outcomes
for Mesothelioma
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+40%
Remission Rate
+5%
Common Side Effects
Fatigue
+40%
Diarrhea
+30%
Rash
+25%
Nausea
+20%
Hypothyroidism
+12%
Pneumonitis
+7%
Colitis
+6%
Active Clinical Trials
9 active trials recruiting for Nivolumab + Ipilimumab in Mesothelioma
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
NCT03918252ACTIVE NOT RECRUITINGPHASE2
30 participants
INTERVENTIONAL
Baltimore, United States +2 more
Started: Oct 2, 2019
A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
NCT05136677ACTIVE NOT RECRUITINGPHASE2
100 participants
INTERVENTIONAL
Beijing, China +20 more
Started: Jan 25, 2022
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
NCT04300244ACTIVE NOT RECRUITINGPHASE2
118 participants
INTERVENTIONAL
Perth, Australia +6 more
Started: May 4, 2020
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728RECRUITINGPHASE3
825 participants
INTERVENTIONAL
Phoenix, United States +177 more
Started: Nov 9, 2023
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
NCT04665206RECRUITINGPHASE1, PHASE2
336 participants
INTERVENTIONAL
San Francisco, United States +11 more
Started: Mar 24, 2021
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
NCT06362369RECRUITINGPHASE1, PHASE2
126 participants
INTERVENTIONAL
Lake Mary, United States +3 more
Started: Aug 23, 2024
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
NCT05647265RECRUITINGPHASE2
26 participants
INTERVENTIONAL
Anchorage, United States +125 more
Started: Nov 27, 2024
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
NCT03907852ACTIVE NOT RECRUITINGPHASE1, PHASE2
57 participants
INTERVENTIONAL
San Francisco, United States +10 more
Started: Apr 15, 2019
NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study
NCT07121374RECRUITINGPHASE1, PHASE2
37 participants
INTERVENTIONAL
Edegem, Belgium
Started: Jul 22, 2025
Completed Clinical Trials
9 completed trials for Nivolumab + Ipilimumab in Mesothelioma
Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients
NCT02716272COMPLETEDPHASE2
125 participants
INTERVENTIONAL
Angers, France +21 more
Started: Mar 24, 2016
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
NCT05041062COMPLETEDPHASE2
2 participants
INTERVENTIONAL
Chicago, United States
Started: Dec 1, 2021
Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma
NCT03048474COMPLETEDPHASE2
36 participants
INTERVENTIONAL
Amsterdam, Netherlands
Started: Sep 1, 2016
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
NCT02899299COMPLETEDPHASE3
605 participants
INTERVENTIONAL
San Francisco, United States +108 more
Started: Nov 29, 2016
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
NCT04334759COMPLETEDPHASE3
214 participants
INTERVENTIONAL
La Jolla, United States +56 more
Started: Feb 18, 2021
A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)
NCT05324436COMPLETED
75 participants
OBSERVATIONAL
Shinjuku-ku, Japan
Started: Jan 8, 2022
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
NCT03241173COMPLETEDPHASE1, PHASE2
52 participants
INTERVENTIONAL
Birmingham, United States +14 more
Started: Oct 9, 2017
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
NCT03126110COMPLETEDPHASE1, PHASE2
145 participants
INTERVENTIONAL
Los Angeles, United States +37 more
Started: Apr 25, 2017
Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)
NCT05308966COMPLETED
204 participants
OBSERVATIONAL
Aix-en-Provence, France +62 more
Started: May 3, 2022